GGrantIndex
← Leaderboards

Bettie M. Steinberg

Long Island Jewish Medical Center

$8,670,531
Attributed
$8,670,531
Total exposure
11
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.5M · FY200713
$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13

Funding mix

By agency

NIH$13,810,171 · 12

By mechanism

P50$8,038,802 · 3
U01$3,812,690 · 1
R01$1,866,328 · 1
M01$61,091 · 6
R13$31,260 · 1

Top collaborators

No co-investigators on record.

Most similar at Long Island Jewish Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Human Papillomavirus

Research focus

Human PapillomavirusLarynx NeoplasmsVirus Related Neoplasm /CancerInhibitor/AntagonistCelecoxibRecurrencePapillomaRespiratorySourceResearch PersonnelRespiratory PapillomaGrowthMolecularLesionRecurrent DiseaseCervical DysplasiaBenignDinoprostoneCyclooxygenase 2PreventFunctional DisorderExcisionIn VitroResponse

Grant awards (32)

Human Papillomavirus Infection and Expression of COX-2$320,761
R01 · FY2013 · DC · contact PI
Human Papillomavirus Infection and Expression of COX-2$337,644
R01 · FY2012 · DC · contact PI
Celecoxib therapy for patients with recurrent respiratory papillomatosis$584,673
U01 · FY2011 · DC · contact PI
Human Papillomavirus Infection and Expression of COX-2$337,644
R01 · FY2011 · DC · contact PI
Celecoxib therapy for patients with recurrent respiratory papillomatosis$802,098
U01 · FY2010 · DC · contact PI
Human Papillomavirus Infection and Expression of COX-2$348,806
R01 · FY2010 · DC · contact PI
TISSUE BANKING FOR PATIENTS WITH LARYNGEAL AND TRACHEAL DISEASE$25,012
M01 · FY2010 · RR · contact PI
A MULTICENTERED RANDOMIZED STUDY OF CELEBREX (CELECOXIB)$11,869
M01 · FY2010 · RR · contact PI
Celecoxib therapy for patients with recurrent respiratory papillomatosis$945,569
U01 · FY2009 · DC · contact PI
Human Papillomavirus Infection and Expression of COX-2$352,153
R01 · FY2009 · DC · contact PI
Human Papillomavirus Infection and Expression of COX-2$169,320
R01 · FY2009 · DC · contact PI
TISSUE BANKING FROM PATIENTS WITH LARYNGEAL AND TRACHEAL DISEASE$10,727
M01 · FY2009 · RR · contact PI
A STUDY OF CELEBREX IN PATIENTS WITH RESPIRATORY PAPILLOMATOSIS$5,196
M01 · FY2009 · RR · contact PI
Celecoxib therapy for patients with recurrent respiratory papillomatosis$861,962
U01 · FY2008 · DC · contact PI
TISSUE BANKING AND ANALYSIS PROTOCOL FROM PATIENTS WITH LARYNGEAL AND TRACHEAL D$5,525
M01 · FY2008 · RR · contact PI
A MULTICENTERED RANDOMIZED STUDY OF CELEBREX (CELECOXIB)$2,762
M01 · FY2008 · RR · contact PI
Celecoxib therapy for patients with recurrent respiratory papillomatosis$618,388
U01 · FY2007 · DC · contact PI
PAPILLOMAS FROM THE UPPER RESPIRATORY TRACT$100,000
P50 · FY2004 · DC
PAPILLOMAS FROM THE UPPER RESPIRATORY TRACT$1,261,970
P50 · FY2003 · DC
PAPILLOMAS FROM THE UPPER RESPIRATORY TRACT$1,270,192
P50 · FY2002 · DC
CORE--TISSUE CULTURE$408,465
P50 · FY2002 · DC
REGULATION OF PAPILLOMAVIRUS EXPRESSION BY EPIDERMAL GROWTH FACTOR$408,465
P50 · FY2002 · DC
Sixth Research workshop on Head and Neck Cancer$31,260
R13 · FY2002 · DE
PAPILLOMAS FROM THE UPPER RESPIRATORY TRACT$1,245,073
P50 · FY2001 · DC
CORE--TISSUE CULTURE$408,465
P50 · FY2001 · DC
REGULATION OF PAPILLOMAVIRUS EXPRESSION BY EPIDERMAL GROWTH FACTOR$408,465
P50 · FY2001 · DC
PAPILLOMAS FROM THE UPPER RESPIRATORY TRACT$1,212,405
P50 · FY2000 · DC
CORE--TISSUE CULTURE$408,465
P50 · FY2000 · DC
REGULATION OF PAPILLOMAVIRUS EXPRESSION BY EPIDERMAL GROWTH FACTOR$408,465
P50 · FY2000 · DC
CORE--TISSUE CULTURE$224,186
P50 · FY2000 · DC
REGULATION OF PAPILLOMAVIRUS EXPRESSION BY EPIDERMAL GROWTH FACTOR$224,186
P50 · FY2000 · DC
PAPILLOMAS FROM THE UPPER RESPIRATORY TRACT$50,000
P50 · FY2000 · DC